Experiencing a first episode of PE entails a substantial risk of VTE recurrence and case fatality [1]. “Guidelines do not really take into account all the variability between patients, e.g. for a patient with an unprovoked PE, a life-long anticoagulant therapy is recommended, but only one third of these patients will have benefits from this treatment, leaving the others exposed to hard to justify haemorrhagic risks,” Dr Robin Chaux (University Hospital St. Etienne, France) explained, pointing to a need of improved scores to predict recurrence [2]. A promising candidate for risk stratification is the PVOI level.
“In literature, significant associations were found between PVOI and VTE recurrence, but the results are still quite discordant between studies,” said Dr Chaux. Furthermore, cut-off values that are used also vary between studies [3-5]. So, apart from evaluating PVOI as potential independent risk factor for VTE recurrence, this analysis by Dr Chaux and colleagues set out to find discriminating threshold values of PVOI to estimate VTE recurrence [1].
To create a substantial sample size, the investigators pooled data of 922 patients from 2 observational studies and 1 randomised controlled trial [3,4,6]. An initial PVOI was determined at the index PE and residual PVOI after 3-6 months of initial anticoagulation therapy. VTE recurrence was defined as objectively confirmed PE or deep vein thrombosis. Study subjects had a history of unprovoked PE in 64.9%.
VTE recurred in 16.2% of patients, and 47.1% received extended anticoagulation over >12 months. Initial PVOI >35% (HR 1.61; 95% transition HR 1.07-2.43) and residual PVOI >5% (HR 1.63; 95% CI 1.06-2.50) were both significantly associated with the risk of VTE recurrence. “So, we have found that initial PVOI and residual PVOI seem to be independent predictors of VTE recurrence after first PE,” said Dr Chaux. He concluded, “For the future, we hope that these results, maybe not alone, will help to more accurately detect patients with high risk of VTE recurrence and provide help in clinical decision-making for adapting anticoagulation therapy.”
- Prandoni P, et al. Haematologica. 2007;92:199-205.
- Chaux R. OC10.1, ISTH Virtual Congress 2020, 12-14 July.
- Tromeur C, et al. Eur Respir J. 2018;51:1701202.
- Chopard R, et al. Am J Cardiol. 2017;119:1883-1889.
- Raj L, et al. Thromb Haemost. 2019;119:1489-1497.
- Planquette B, et al. Thromb Res. 2016;148:70-75.
Posted on
Previous Article
« Less diagnostic delay in CTEPH diagnosis with novel algorithm Next Article
Increased rates of arterial thromboembolism in cancer patients »
« Less diagnostic delay in CTEPH diagnosis with novel algorithm Next Article
Increased rates of arterial thromboembolism in cancer patients »
Table of Contents: ISTH 2020
Featured articles
Haemophilia and Rare Bleeding Disorders
Novel gene therapy leads to normal FIX activity levels in severe haemophilia B
Haemophilia gene therapy: progress and obstacles
Recombinant factor VIII safe and effective in PUPs A-LONG study
What’s New in Anticoagulation
Finding the sweet spot of anticoagulation in AF patients with ACS
Lower embryopathy risk with DOAC versus VKA during pregnancy
Higher thrombotic risk in NSCLC patient with ALK rearrangement
COVID-19 and Thrombosis
Crosstalk between inflammation and coagulation in severe COVID-19 infections
COVID-19 associated with higher VTE rates relative to influenza
Therapeutic anticoagulation not associated with lower mortality rates in COVID-19 ICU patients
COVID-19 not associated with heightened VTE risk after discharge
What’s New in Venous Thromboembolism
Residual pulmonary obstruction may predict risk of VTE recurrence
Less diagnostic delay in CTEPH diagnosis with novel algorithm
Risk of checkpoint inhibitor-associated thromboembolic events important for cancer prognosis
Pearls of the Posters
Surgical bleeding risk most important determinant of bleeding outcomes
Similar bleeding rates in patients with VTE and AF treated with DOACs
Physical rehabilitation improves health outcomes after pulmonary embolism
Guidelines adherence reduces bleeding risk after surgery and childbirth for VWD patients
Factor V Leiden mutation linked to atrial fibrillation
Increased rates of arterial thromboembolism in cancer patients
Related Articles
September 8, 2020
Factor V Leiden mutation linked to atrial fibrillation
September 8, 2020
Letter from the Editor
September 8, 2020
COVID-19 not associated with heightened VTE risk after discharge
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com